Stelara (ustekinumab) is a prescription drug that treats autoimmune conditions such as plaque psoriasis. You typically inject it subcutaneously (under your skin) or receive it intravenously ...

Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

The average annual out-of-pocket cost for Stelara, an injectable drug that treats autoimmune conditions, rose the most from $709 per enrollee to $2,058. For non-Medicare U.S. patients, Stelara can ...

Several headwinds are impacting the company, including generic competition for its blockbuster drug Stelara, the ongoing talc lawsuit (which could see a final decision in the first half of the ...

Overall, global Stelara sales dropped 14.7% year-over-year to roughly $2.3 billion in 2024’s fourth quarter. For the full 12-month earnings period, Stelara sales slipped around 4.6% to $10.4 ...

The pharmaceutical company’s latest earnings exceeded Wall Street’s expectations as it braces for one of its top-selling ...

Investors are watching biosimilar competition with immunology drug Stelara, which extended to the key US market in January. We assume a more than $3 billion decline in global Stelara sales in 2025.